MA-NEURALA
24.3.2021 14:02:15 CET | Business Wire | Press release
Today, Neurala , the leader in vision AI software, announced a collaboration with FLIR Systems Inc. to deliver a full software and hardware stack AI-based industrial imaging solution. Neurala’s vision AI software unlocks the power of deep learning with no-AI-expertise-required, and now supports the creation of neural networks that can be deployed directly onto FLIR Firefly DL cameras. As a leader in machine vision cameras, FLIR Firefly DL cameras are remarkably compact with built-in inference on the edge capabilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210324005235/en/
Through the collaboration, Neurala and FLIR are delivering a faster, more cost-effective entry point for customers looking to deploy deep learning on the production line. This comes at a time when manufacturers are focused on AI and automation to provide flexibility to cope with production constraints, supply chain disruptions, and scattered workforce availability.
The new solution allows customers to rapidly create deep learning models using Neurala’s Brain Builder on the VIA platform with little data and no AI expertise. These models can be directly uploaded to a FLIR Firefly DL camera using the free FLIR Spinnaker SDK. As a result, neural networks can be deployed for a wide variety of applications, including printed circuit board (PCB) inspection, detection of foreign objects, identification of surface level metal defects and product uniformity issues. With the ability to deploy directly onto the compact FLIR Firefly DL camera, an intelligent, automated inspection point can be placed practically anywhere in-line and quickly reconfigured for new applications.
“The rise of Industry 4.0 has challenged manufacturers to rethink the tools and systems they are using as part of their workflow. With cameras and sensors gathering product data and analyzing the overall health of industrial equipment, manufacturers have realized the power of AI to draw actionable insights from this data,” said Max Versace, CEO and co-founder of Neurala. “We are thrilled to collaborate with FLIR to enable customers to capitalize on the data their machines are collecting as they look to further automate their manufacturing processes.”
“Being one of the world’s first machine vision manufacturers with an inference on the edge solution, we are constantly looking for ways to help our customers stay at the cutting edge,” said Sadiq Panjwani, Vice President, Components Business, FLIR Systems. “Our collaboration with Neurala on a simplified and accessible full-stack deep learning solution is another step in that direction, bringing customers the advanced machine vision techniques required for today’s highly automated industrial environments.”
To learn more about Neurala’s Vision AI software for FLIR Firefly DL machine vision cameras, click here .
About Neurala
Neurala is a pioneer in vision AI software. On a mission to make AI more applicable and useful in real-world applications, Neurala helps industrial companies improve their quality inspection process, with technology that dramatically reduces the time, cost and skills required to build and maintain production-quality custom vision AI solutions. Founded in 2006, Neurala’s research team invented Lifelong-DNN™ (L-DNN) technology, which lowers the data requirements for AI model development and enables continuous learning in the cloud or at the edge.
Follow Neurala on Twitter (@Neurala) and on Facebook , YouTube and LinkedIn , or subscribe to our blog to receive more information about the latest developments at Neurala.
For a more in depth look at Neurala’s vision AI software, request a virtual demo .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005235/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 15:37:00 CEST | Press release
The new SpeechLive Legal AI Assistant reduces the administrative burden on legal professionals through customizable document drafting powered by speech recognition tuned for legal terminology Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
